Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 77 articles:
HTML format
Text format



Single Articles


    June 2017
  1. NABHAN C, Mato AR
    Economic Modeling of the Cost of Chronic Lymphocytic Leukemia Therapy: It Is About the Model.
    J Clin Oncol. 2017;35:1863-1864.
    PubMed     Text format    


    May 2017
  2. WINICK N, Devidas M, Chen S, Maloney K, et al
    Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.
    J Clin Oncol. 2017 May 23:JCO2016714774. doi: 10.1200/JCO.2016.71.4774.
    PubMed     Text format     Abstract available


  3. RITCHIE EK, Guerin A, Wolff J, Joseph G, et al
    Role of Cost-Sharing Subsidies on the Initiation of and Adherence to Tyrosine Kinase Inhibitor Therapy by Medicare Beneficiaries With Chronic Myeloid Leukemia.
    J Clin Oncol. 2017;35:1744-1745.
    PubMed     Text format    


  4. BOUDREAU JE, Giglio F, Gooley TA, Stevenson PA, et al
    KIR3DL1/ HL A-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation.
    J Clin Oncol. 2017 May 18:JCO2016707059. doi: 10.1200/JCO.2016.70.7059.
    PubMed     Text format     Abstract available


  5. SEKERES MA, Othus M, List AF, Odenike O, et al
    Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
    J Clin Oncol. 2017 May 9:JCO2015662510. doi: 10.1200/JCO.2015.66.2510.
    PubMed     Text format     Abstract available


    April 2017
  6. SCOTT BL, Pasquini MC, Logan BR, Wu J, et al
    Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    J Clin Oncol. 2017;35:1154-1161.
    PubMed     Text format     Abstract available


  7. BRADSTOCK KF, Link E, Di Iulio J, Szer J, et al
    Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.
    J Clin Oncol. 2017 Apr 3:JCO2016706374. doi: 10.1200/JCO.2016.70.6374.
    PubMed     Text format     Abstract available


    March 2017
  8. MARTINELLI G, Boissel N, Chevallier P, Ottmann O, et al
    Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter St
    J Clin Oncol. 2017 Mar 29:JCO2016693531. doi: 10.1200/JCO.2016.69.3531.
    PubMed     Text format     Abstract available


  9. LANDIER W, Hageman L, Chen Y, Kornegay N, et al
    Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1.
    J Clin Oncol. 2017 Mar 24:JCO2016717579. doi: 10.1200/JCO.2016.71.7579.
    PubMed     Text format     Abstract available


  10. IACOBUCCI I, Mullighan CG
    Genetic Basis of Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2017;35:975-983.
    PubMed     Text format     Abstract available


  11. TIACCI E, Pettirossi V, Schiavoni G, Falini B, et al
    Genomics of Hairy Cell Leukemia.
    J Clin Oncol. 2017;35:1002-1010.
    PubMed     Text format     Abstract available


  12. BULLINGER L, Dohner K, Dohner H
    Genomics of Acute Myeloid Leukemia Diagnosis and Pathways.
    J Clin Oncol. 2017;35:934-946.
    PubMed     Text format     Abstract available


  13. LAZARIAN G, Guieze R, Wu CJ
    Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2017;35:984-993.
    PubMed     Text format     Abstract available


  14. LENZ G
    Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2017 Mar 14:JCO2016720102. doi: 10.1200/JCO.2016.72.0102.
    PubMed     Text format    


    February 2017
  15. THOMAS X, de Botton S, Chevret S, Caillot D, et al
    Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission.
    J Clin Oncol. 2017 Feb 21:JCO2016704551. doi: 10.1200/JCO.2016.70.4551.
    PubMed     Text format     Abstract available


  16. WOYACH JA, Ruppert AS, Guinn D, Lehman A, et al
    BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2017 Feb 13:JCO2016702282. doi: 10.1200/JCO.2016.70.2282.
    PubMed     Text format     Abstract available


  17. JURCIC JG
    Androgen Maintenance Therapy for Acute Myeloid Leukemia.
    J Clin Oncol. 2017;35:381-383.
    PubMed     Text format    


  18. PIGNEUX A, Bene MC, Guardiola P, Recher C, et al
    Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study.
    J Clin Oncol. 2017;35:387-393.
    PubMed     Text format     Abstract available


    January 2017
  19. LICHTMAN MA
    Clonal Cytopenias and Oligoblastic Myelogenous Leukemia (myelodysplasia) Have Neoplastic, not Hyperplastic, Erythropoiesis.
    J Clin Oncol. 2017 Jan 30:JCO2016704056. doi: 10.1200/JCO.2016.70.4056.
    PubMed     Text format    


  20. ETIENNE G, Guilhot J, Rea D, Rigal-Huguet F, et al
    Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.
    J Clin Oncol. 2017;35:298-305.
    PubMed     Text format     Abstract available


  21. DEANGELO DJ
    Tailored Approaches to Induction Therapy for Acute Promyelocytic Leukemia.
    J Clin Oncol. 2017 Jan 17:JCO2016684761. doi: 10.1200/JCO.2016.68.4761.
    PubMed     Text format     Abstract available


  22. BALSAT M, Renneville A, Thomas X, de Botton S, et al
    Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.
    J Clin Oncol. 2017;35:185-193.
    PubMed     Text format     Abstract available


  23. SOPPER S, Mustjoki S, White D, Hughes T, et al
    Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia.
    J Clin Oncol. 2017;35:175-184.
    PubMed     Text format     Abstract available


  24. O'CONNOR D, Moorman AV, Wade R, Hancock J, et al
    Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2017 Jan 3:JCO2016696278.
    PubMed     Text format     Abstract available


    December 2016
  25. WINN AN, Keating NL, Dusetzina SB
    Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
    J Clin Oncol. 2016;34:4323-4328.
    PubMed     Text format     Abstract available


  26. VON STACKELBERG A, Locatelli F, Zugmaier G, Handgretinger R, et al
    Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2016;34:4381-4389.
    PubMed     Text format     Abstract available


  27. MEHTA-SHAH N, Horwitz SM
    Lenalidomide in Adult T-Cell Leukemia/Lymphoma.
    J Clin Oncol. 2016;34:4066-4067.
    PubMed     Text format    


    November 2016
  28. PULTE D, Jansen L
    Population-Level Survival for Patients With Chronic Myeloid Leukemia: Higher Survival in Sweden Than Internationally.
    J Clin Oncol. 2016 Nov 28:JCO2016696849.
    PubMed     Text format    


  29. ROBERTS KG, Gu Z, Payne-Turner D, McCastlain K, et al
    High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.
    J Clin Oncol. 2016 Nov 21:JCO2016690073.
    PubMed     Text format     Abstract available


  30. CHEN Q, Jain N, Ayer T, Wierda WG, et al
    Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States.
    J Clin Oncol. 2016 Nov 21:JCO2016682856.
    PubMed     Text format     Abstract available


    September 2016
  31. ISHIDA T, Fujiwara H, Nosaka K, Taira N, et al
    Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002.
    J Clin Oncol. 2016 Sep 12. pii: JCO677732.
    PubMed     Text format     Abstract available


    August 2016
  32. WIERDA WG
    Minimal Residual Disease Provides Treatment Focus for Next Chronic Lymphocytic Leukemia Advances.
    J Clin Oncol. 2016 Aug 29. pii: JCO691972.
    PubMed     Text format    


  33. KOVACS G, Robrecht S, Fink AM, Bahlo J, et al
    Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
    J Clin Oncol. 2016 Aug 29. pii: JCO671305.
    PubMed     Text format     Abstract available


  34. GANZEL C, Manola J, Douer D, Rowe JM, et al
    Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008.
    J Clin Oncol. 2016 Aug 29. pii: JCO675892.
    PubMed     Text format     Abstract available


  35. SUZUKI K, Okuno Y, Kawashima N, Muramatsu H, et al
    MEF2D-BCL9 Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents.
    J Clin Oncol. 2016 Aug 9. pii: JCO665547.
    PubMed     Text format     Abstract available


  36. FUJI S, Inoue Y, Utsunomiya A, Moriuchi Y, et al
    Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality.
    J Clin Oncol. 2016 Aug 9. pii: JCO678250.
    PubMed     Text format     Abstract available


  37. ALEXANDER TB, Lacayo NJ, Choi JK, Ribeiro RC, et al
    Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia.
    J Clin Oncol. 2016 Aug 9. pii: JCO675066.
    PubMed     Text format     Abstract available


    July 2016
  38. NIEDZWIECKI D, Frankel WL, Venook AP, Ye X, et al
    Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).
    J Clin Oncol. 2016 Jul 18. pii: JCO654699.
    PubMed     Text format     Abstract available


  39. PLATZBECKER U, Avvisati G, Cicconi L, Thiede C, et al
    Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
    J Clin Oncol. 2016 Jul 11. pii: JCO671982.
    PubMed     Text format     Abstract available


    June 2016
  40. GERBING RB, Alonzo TA, Sung L, Gamis AS, et al
    Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children's Oncology Group.
    J Clin Oncol. 2016 Jun 27. pii: JCO669622.
    PubMed     Text format     Abstract available


  41. BOWER H, Bjorkholm M, Dickman PW, Hoglund M, et al
    Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.
    J Clin Oncol. 2016 Jun 20. pii: JCO662866.
    PubMed     Text format     Abstract available


  42. PIETERS R, de Groot-Kruseman H, Van der Velden V, Fiocco M, et al
    Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group.
    J Clin Oncol. 2016 Jun 6. pii: JCO646364.
    PubMed     Text format     Abstract available


  43. TRAMSEN L, Salzmann-Manrique E, Bochennek K, Klingebiel T, et al
    Lack of Effectiveness of Neutropenic Diet and Social Restrictions as Anti-Infective Measures in Children With Acute Myeloid Leukemia: An Analysis of the AML-BFM 2004 Trial.
    J Clin Oncol. 2016 Jun 6. pii: JCO667881.
    PubMed     Text format     Abstract available


  44. KRULL KR, Cheung YT, Liu W, Fellah S, et al
    Chemotherapy Pharmacodynamics and Neuroimaging and Neurocognitive Outcomes in Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2016 Jun 6. pii: JCO654574.
    PubMed     Text format     Abstract available


    May 2016
  45. CORTES JE, Saglio G, Kantarjian HM, Baccarani M, et al
    Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial.
    J Clin Oncol. 2016 May 23. pii: JCO648899.
    PubMed     Text format     Abstract available


  46. WARRIS LT, van den Heuvel-Eibrink MM, Aarsen FK, Pluijm SM, et al
    Hydrocortisone as an Intervention for Dexamethasone-Induced Adverse Effects in Pediatric Patients With Acute Lymphoblastic Leukemia: Results of a Double-Blind, Randomized Controlled Trial.
    J Clin Oncol. 2016 May 9. pii: JCO660761.
    PubMed     Text format     Abstract available


    April 2016
  47. LIU C, Yang W, Devidas M, Cheng C, et al
    Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2016 Apr 25. pii: JCO645812.
    PubMed     Text format     Abstract available


  48. ROYER B, Minvielle S, Diouf M, Roussel M, et al
    Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myelome.
    J Clin Oncol. 2016 Apr 25. pii: JCO631929.
    PubMed     Text format     Abstract available


  49. MUSTO P
    Progress in the Treatment of Primary Plasma Cell Leukemia.
    J Clin Oncol. 2016 Apr 25. pii: JCO666115.
    PubMed     Text format    


  50. LARSEN EC, Devidas M, Chen S, Salzer WL, et al
    Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232.
    J Clin Oncol. 2016 Apr 25. pii: JCO624544.
    PubMed     Text format     Abstract available


  51. STYCZYNSKI J, Tridello G, Gil L, Ljungman P, et al
    Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the E
    J Clin Oncol. 2016 Apr 18. pii: JCO642405.
    PubMed     Text format     Abstract available


  52. BRUDNO JN, Somerville RP, Shi V, Rose JJ, et al
    Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.
    J Clin Oncol. 2016;34:1112-21.
    PubMed     Text format     Abstract available


    March 2016
  53. WILSON CL, Chemaitilly W, Jones KE, Kaste SC, et al
    Modifiable Factors Associated With Aging Phenotypes Among Adult Survivors of Childhood Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2016 Mar 21. pii: JCO649525.
    PubMed     Text format     Abstract available


  54. FATHI AT, Lin WM, Durazzo T, Piris A, et al
    Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.
    J Clin Oncol. 2016;34:e70-2.
    PubMed     Text format    


  55. HILL BG, Shen AQ, El Rassi F, Khoury HJ, et al
    Sustained Complete Molecular Remission After Discontinuation of Tyrosine Kinase Inhibitors in Blast-Phase Chronic Myeloid Leukemia.
    J Clin Oncol. 2016;34:e68-9.
    PubMed     Text format    


  56. POLLARD JA, Loken M, Gerbing RB, Raimondi SC, et al
    CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.
    J Clin Oncol. 2016;34:747-55.
    PubMed     Text format     Abstract available


  57. JAIN P, Ok CY, Konoplev S, Patel KP, et al
    Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?
    J Clin Oncol. 2016;34:e57-60.
    PubMed     Text format    


    February 2016
  58. JASIELEC JK, Larson RA
    Dasatinib-Related Pulmonary Toxicity Mimicking an Atypical Infection.
    J Clin Oncol. 2016;34:e46-8.
    PubMed     Text format    


  59. MILLER TP, Li Y, Kavcic M, Troxel AB, et al
    Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia.
    J Clin Oncol. 2016 Feb 16. pii: JCO655860.
    PubMed     Text format     Abstract available


  60. JACOLA LM, Krull KR, Pui CH, Pei D, et al
    Longitudinal Assessment of Neurocognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia Treated on a Contemporary Chemotherapy Protocol.
    J Clin Oncol. 2016 Feb 8. pii: JCO643205.
    PubMed     Text format     Abstract available


  61. VAN LEEUWEN FE, Ronckers CM
    Anthracyclines and Alkylating Agents: New Risk Factors for Breast Cancer in Childhood Cancer Survivors?
    J Clin Oncol. 2016 Feb 1. pii: JCO650465.
    PubMed     Text format    


    January 2016
  62. AMADORI S, Suciu S, Selleslag D, Aversa F, et al
    Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.
    J Clin Oncol. 2016 Jan 25. pii: JCO640060.
    PubMed     Text format     Abstract available


  63. KOH JW, Chin F, Teh YH, Chan MY, et al
    Second neoplasms in survivors of childhood acute lymphoblastic leukemia treated with both chemotherapy and radiotherapy.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  64. BRINKMAN TM, Cheung YT, Pui CH, Hudson MM, et al
    Functional consequence of cognitive impairment in survivors of childhood acute lymphoblastic leukemia (ALL): The role of cancer symptoms as mediators.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  65. SMITH BD, Hourigan CS, Gojo I, Pratz KW, et al
    A single-center survey of health-related quality of life among acute myeloid leukemia survivors in first complete remission.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  66. ALLAN JN, Howes AJ, Mahler M, Wildgust MA, et al
    Comparing overall survival (OS) outcomes in patients with newly diagnosed chronic lymphocytic leukemia (CLL) with normal life expectancy.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  67. VORA A, Andreano A, Pui CH, Hunger SP, et al
    Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy.
    J Clin Oncol. 2016 Jan 11. pii: JCO642850.
    PubMed     Text format     Abstract available


    December 2015
  68. ASSELIN BL, Devidas M, Chen L, Franco VI, et al
    Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology
    J Clin Oncol. 2015 Dec 23. pii: JCO608851.
    PubMed     Text format     Abstract available


  69. O'DWYER KM, Advani AS
    When to Treat Adults Like Children: Optimizing Therapy for Lymphoblastic Lymphoma in Young Adults.
    J Clin Oncol. 2015 Dec 23. pii: JCO647156.
    PubMed     Text format     Abstract available


  70. HENDERSON TO, Moskowitz CS, Chou JF, Bradbury AR, et al
    Breast Cancer Risk in Childhood Cancer Survivors Without a History of Chest Radiotherapy: A Report From the Childhood Cancer Survivor Study.
    J Clin Oncol. 2015 Dec 23. pii: JCO623314.
    PubMed     Text format     Abstract available


  71. ARAKI D, Wood BL, Othus M, Radich JP, et al
    Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
    J Clin Oncol. 2015 Dec 14. pii: JCO633826.
    PubMed     Text format     Abstract available


  72. BASSAN R
    Using Minimal Residual Disease to Improve Treatment Response Definitions and Hematopoietic Cell Transplantation Strategy in Acute Leukemia.
    J Clin Oncol. 2015 Dec 14. pii: JCO648907.
    PubMed     Text format    


  73. LEPRETRE S, Touzart A, Vermeulin T, Picquenot JM, et al
    Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.
    J Clin Oncol. 2015 Dec 7. pii: JCO615385.
    PubMed     Text format     Abstract available


    November 2015
  74. CAYWOOD EH, Kolb EA
    Challenges in Converting Acute Myeloid Leukemia (AML) Genomics Into AML Clinical Trials.
    J Clin Oncol. 2015 Nov 16. pii: JCO.2015.63.9252.
    PubMed     Text format    


  75. CHEN X, Xie H, Estey EH
    Reply to D. Przepiorka et al.
    J Clin Oncol. 2015;33:3676-7.
    PubMed     Text format    


    August 2015
  76. CHOW EJ, Asselin BL, Schwartz CL, Doody DR, et al
    Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group.
    J Clin Oncol. 2015;33:2639-45.
    PubMed     Text format     Abstract available


  77. KREMER LC, van Dalen EC
    Dexrazoxane in Children With Cancer: From Evidence to Practice.
    J Clin Oncol. 2015;33:2594-6.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: